Olansek en es it fr

Olansek Brand names, Olansek Analogs

Olansek Brand Names Mixture

  • No information avaliable

Olansek Chemical_Formula


Olansek RX_link


Olansek fda sheet

Olansek FDA

Olansek msds (material safety sheet)

Olansek Synthesis Reference

J. K. Chakrabarti et al., U.S. Pat. 5,229,382 (1991)

Olansek Molecular Weight

312.434 g/mol

Olansek Melting Point


Olansek H2O Solubility

No information avaliable

Olansek State


Olansek LogP


Olansek Dosage Forms

Tablet (oral)

Olansek Indication

For the treatment of schizophrenia and manic depression (bipolar disorder).

Olansek Pharmacology

Olanzapine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, olanzapine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors.

Olansek Absorption

Well absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.

Olansek side effects and Toxicity

No information avaliable

Olansek Patient Information


Physicians are advised to discuss the following issues with patients for whom they prescribe

Orthostatic Hypotension: Patients should be advised of the risk of orthostatic hypotension,
especially during the period of initial dose titration and in association with the use of
concomitant drugs that may potentiate the orthostatic effect of olanzapine, e.g., diazepam
or alcohol.

Interference with Cognitive and Motor Performance: Because olanzapine has the potential to
impair judgment, thinking, or motor skills, patients should be cautioned about operating
hazardous machinery, including automobiles, until they are reasonably certain that olanzapine
therapy does not affect them adversely.

Pregnancy: Patients should be advised to notify their physician if they become pregnant or
intend to become pregnant during therapy with olanzapine.

Nursing: Patients should be advised not to breast-feed an infant if they are taking olanzapine.

Concomitant Medication: Patients should be advised to inform their physicians if they are taking,
or plan to take, any prescription or over-the-counter drugs, since there is a potential for

Alcohol: Patients should be advised to avoid alcohol while taking olanzapine.

Heat Exposure and Dehydration: Patients should be advised regarding appropriate care in avoiding
overheating and dehydration.

Phenylketonurics: ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) contains phenylalanine
(0.34, 0.45, 0.67, or 0.90 mg per 5, 10, 15, or 20mg tablet, respectively).

Laboratory Tests

Periodic assessment of transaminases is recommended in patients with significant hepatic disease.

Olansek Organisms Affected

Humans and other mammals